Teva Presents Latest Schizophrenia Portfolio Data Including Real-World Outcomes with UZEDY® (risperidone) Showing Lower Rates of and Longer Time to Relapse Compared to Oral Treatment Options and New Phase 3 SOLARIS Data Showing No Incidence of PDSS with TEV-‘749 (olanzapine) to Date
Discussion
New Portfolio and Lower Longer Outcomes Relapse to Phase SOLARIS to to Showing Rates Options Data of Compared of Incidence 3 No Treatment Presents Teva (olanzapine) Date
https://financialpost.com/globe-newswire/teva-presents-latest-schizophrenia-portfolio-data-including-real-world-outcomes-with-uzedy-risperidone-showing-lower-rates-of-and-longer-time-to-relapse-compared-to-oral-treatment-options-and with UZEDY® Time Including and (risperidone) PDSS Schizophrenia TEV-‘749 Oral Real-World Showing Data with Latest